Pulmonary Arterial Hypertension Market is expected to reach US$ 10,889.08 million by 2028

The pulmonary arterial hypertension market is projected to reach US$ 10,889.08 million by 2028; registering at a CAGR of 5.8% from 2022 to 2028, according to a new research study conducted by The Insight Partners

Prostacyclin and Prostacyclin Analogs Segment Dominated Pulmonary Arterial Hypertension Market in 2021

The growing incidence of pulmonary arterial hypertension and rising approvals of pulmonary arterial hypertension drugs are contributing to the market growth. However, side effects of drugs used for the treatment of pulmonary arterial hypertension restrict the market growth.

Growing Incidence of Pulmonary Arterial Hypertension Propels Market Growth

In pulmonary arterial hypertension (PAH), tiny arteries in lung become thick and narrow. PAH blocks the blood flow through lungs. As a result, blood pressure in the lungs increases, and heart faces difficulties to pump blood through narrowed arteries. Over the time, an individual's heart loses the ability to pump blood throughout the body effectively. PAH usually affects women in the age range from 30 to 60 years. National Organization for Rare Disorders (NORD) stated that the cases of PAH are 3–5 times higher in females than in males. Also, in the US, new cases are projected to occur in one to two people per million per year. The incidence is projected to be the same in Europe. About 500–1,000 new cases of PAH are diagnosed annually in the US.

Pulmonary Arterial Hypertension Market, by Region, 2021 (%)

Source: The Insight Partners Analysis

Further, according to an article in European Respiratory Review published in 2019, the incidence of PAH is 2.0 cases per million in the US and 7.6 cases per million in Scotland.

Thus, the growing incidence of pulmonary arterial hypertension is driving the growth of the pulmonary arterial hypertension market.

Johnson & Johnson, Gilead Sciences Inc, United Therapeutics Corp, Bayer AG, Aerami Therapeutics Holdings Inc, Novartis AG, GSK Plc, Teva Pharmaceutical Industries Ltd, Lupin Ltd, and Pfizer Inc are among the key companies operating in the pulmonary arterial hypertension market.

The report segments the pulmonary arterial hypertension market as follows:

The pulmonary arterial hypertension market is segmented on the basis of drug, type, route of administration, distribution channel, and geography. Based on drug, the pulmonary arterial hypertension market is segmented into endothelin receptor antagonists (ERAs), prostacyclin and prostacyclin analogs, sGC stimulators, and pde-5 dipsticks. In 2021, prostacyclin and prostacyclin analogs are likely to account for the largest share of the market and the same segment is also anticipated to register the highest CAGR of 6.6% in the market during the forecast period. The factor driving the prostacyclin and prostacyclin analogs segment mainly include the use of PAH prostacyclin analogs as medications to treat pulmonary arterial hypertension (PAH), a condition of high blood pressure in the arteries that carry deoxygenated blood from the heart to the lungs.

Based on type, the pulmonary arterial hypertension market is bifurcated into branded and generics. Based on route of administration, the market is segmented into oral, intravenous/ subcutaneous, and inhalational. In terms of distribution channel, the pulmonary arterial hypertension market is segmented into hospital pharmacies and clinics, online pharmacies, and retail pharmacies.

In terms of geography, the pulmonary arterial hypertension market is segmented into North America (the US, Canada, and Mexico), Europe (the UK, Germany, France, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (the UAE, Saudi Arabia, South Africa, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).

Contact Us
 
Phone: +1-646-491-9876
Email Id: sales@theinsightpartners.com